#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Kounis syndrome is defined as acute coronary syndromes ( ACS ) induced by hypersensitivity and anaphylactic reaction .
2-1	14-20	Kounis	person|abstract[3]	new|new[3]	coref|coref	3-7|3-7[12_3]
2-2	21-29	syndrome	abstract[3]	new[3]	_	_
2-3	30-32	is	_	_	_	_
2-4	33-40	defined	_	_	_	_
2-5	41-43	as	_	_	_	_
2-6	44-49	acute	abstract[5]	new[5]	appos	2-10[0_5]
2-7	50-58	coronary	person|abstract[5]	new|new[5]	coref	7-8
2-8	59-68	syndromes	abstract[5]	new[5]	_	_
2-9	69-70	(	_	_	_	_
2-10	71-74	ACS	abstract	giv	_	_
2-11	75-76	)	_	_	_	_
2-12	77-84	induced	_	_	_	_
2-13	85-87	by	_	_	_	_
2-14	88-104	hypersensitivity	abstract|abstract[8]	new|new[8]	coref|coref	20-6|20-6[110_8]
2-15	105-108	and	abstract[8]	new[8]	_	_
2-16	109-121	anaphylactic	abstract[8]|event[9]	new[8]|new[9]	coref	10-1[53_9]
2-17	122-130	reaction	abstract[8]|event[9]	new[8]|new[9]	_	_
2-18	131-132	.	_	_	_	_

#Text=Several causes are reported to induce Kounis syndrome , such as medicines , environmental exposures , bee stings , and asthma ( Table 2 ) .
3-1	133-140	Several	abstract[10]	new[10]	_	_
3-2	141-147	causes	abstract[10]	new[10]	_	_
3-3	148-151	are	_	_	_	_
3-4	152-160	reported	_	_	_	_
3-5	161-163	to	_	_	_	_
3-6	164-170	induce	_	_	_	_
3-7	171-177	Kounis	person|abstract[12]	giv|giv[12]	coref|coref	4-14|4-14[23_12]
3-8	178-186	syndrome	abstract[12]	giv[12]	_	_
3-9	187-188	,	abstract[12]	giv[12]	_	_
3-10	189-193	such	abstract[12]	giv[12]	_	_
3-11	194-196	as	abstract[12]	giv[12]	_	_
3-12	197-206	medicines	abstract[12]|substance	giv[12]|new	_	_
3-13	207-208	,	abstract[12]	giv[12]	_	_
3-14	209-222	environmental	abstract[12]|event[14]	giv[12]|new[14]	_	_
3-15	223-232	exposures	abstract[12]|event[14]	giv[12]|new[14]	_	_
3-16	233-234	,	abstract[12]	giv[12]	_	_
3-17	235-238	bee	abstract[12]|animal|event[16]	giv[12]|new|new[16]	_	_
3-18	239-245	stings	abstract[12]|event[16]	giv[12]|new[16]	_	_
3-19	246-247	,	abstract[12]	giv[12]	_	_
3-20	248-251	and	abstract[12]	giv[12]	_	_
3-21	252-258	asthma	abstract[12]|abstract	giv[12]|new	_	_
3-22	259-260	(	_	_	_	_
3-23	261-266	Table	_	_	_	_
3-24	267-268	2	_	_	_	_
3-25	269-270	)	_	_	_	_
3-26	271-272	.	_	_	_	_

#Text=Ayhan Akoz et al. conducted a prospective study and found the incidence of Kounis syndrome in all admissions to be 19.4/100,000 .
4-1	273-278	Ayhan	person[18]	new[18]	_	_
4-2	279-283	Akoz	person[18]	new[18]	_	_
4-3	284-286	et	_	_	_	_
4-4	287-290	al.	person	new	_	_
4-5	291-300	conducted	_	_	_	_
4-6	301-302	a	abstract[20]	new[20]	coref	12-2[71_20]
4-7	303-314	prospective	abstract[20]	new[20]	_	_
4-8	315-320	study	abstract[20]	new[20]	_	_
4-9	321-324	and	_	_	_	_
4-10	325-330	found	_	_	_	_
4-11	331-334	the	abstract[21]	new[21]	_	_
4-12	335-344	incidence	abstract[21]	new[21]	_	_
4-13	345-347	of	abstract[21]	new[21]	_	_
4-14	348-354	Kounis	abstract[21]|person|abstract[23]	new[21]|giv|giv[23]	coref|coref	6-9|6-9[33_23]
4-15	355-363	syndrome	abstract[21]|abstract[23]	new[21]|giv[23]	_	_
4-16	364-366	in	abstract[21]|abstract[23]	new[21]|giv[23]	_	_
4-17	367-370	all	abstract[21]|abstract[23]|event[24]	new[21]|giv[23]|new[24]	_	_
4-18	371-381	admissions	abstract[21]|abstract[23]|event[24]	new[21]|giv[23]|new[24]	_	_
4-19	382-384	to	_	_	_	_
4-20	385-387	be	_	_	_	_
4-21	388-400	19.4/100,000	abstract	new	_	_
4-22	401-402	.	_	_	_	_

#Text=The most common etiology reported was the use of medications , accounting for about 81 % .
5-1	403-406	The	event[26]	new[26]	coref	5-7[27_26]
5-2	407-411	most	event[26]	new[26]	_	_
5-3	412-418	common	event[26]	new[26]	_	_
5-4	419-427	etiology	event[26]	new[26]	_	_
5-5	428-436	reported	event[26]	new[26]	_	_
5-6	437-440	was	_	_	_	_
5-7	441-444	the	event[27]	giv[27]	_	_
5-8	445-448	use	event[27]	giv[27]	_	_
5-9	449-451	of	event[27]	giv[27]	_	_
5-10	452-463	medications	event[27]|substance	giv[27]|new	_	_
5-11	464-465	,	event[27]	giv[27]	_	_
5-12	466-476	accounting	event[27]	giv[27]	_	_
5-13	477-480	for	event[27]	giv[27]	_	_
5-14	481-486	about	event[27]|abstract[29]	giv[27]|new[29]	_	_
5-15	487-489	81	event[27]|abstract[29]	giv[27]|new[29]	_	_
5-16	490-491	%	event[27]|abstract[29]	giv[27]|new[29]	_	_
5-17	492-493	.	_	_	_	_

#Text=In the current concept , three variants of Kounis syndrome have been described .
6-1	494-496	In	_	_	_	_
6-2	497-500	the	abstract[30]	new[30]	coref	19-2[102_30]
6-3	501-508	current	abstract[30]	new[30]	_	_
6-4	509-516	concept	abstract[30]	new[30]	_	_
6-5	517-518	,	_	_	_	_
6-6	519-524	three	abstract[31]	new[31]	_	_
6-7	525-533	variants	abstract[31]	new[31]	_	_
6-8	534-536	of	abstract[31]	new[31]	_	_
6-9	537-543	Kounis	abstract[31]|person|abstract[33]	new[31]|giv|giv[33]	coref|coref	8-3[43_33]|15-11
6-10	544-552	syndrome	abstract[31]|abstract[33]	new[31]|giv[33]	_	_
6-11	553-557	have	_	_	_	_
6-12	558-562	been	_	_	_	_
6-13	563-572	described	_	_	_	_
6-14	573-574	.	_	_	_	_

#Text=Type I variant is characterized by allergy-related coronary spasm without coronary lesions or risk factors .
7-1	575-579	Type	abstract[34]|abstract[35]	new[34]|new[35]	coref|coref	8-3[42_34]|9-1[51_35]
7-2	580-581	I	abstract[34]|abstract[35]	new[34]|new[35]	_	_
7-3	582-589	variant	abstract[35]	new[35]	_	_
7-4	590-592	is	_	_	_	_
7-5	593-606	characterized	_	_	_	_
7-6	607-609	by	_	_	_	_
7-7	610-625	allergy-related	event[37]	new[37]	coref	8-25[49_37]
7-8	626-634	coronary	person|event[37]	giv|new[37]	_	_
7-9	635-640	spasm	event[37]	new[37]	_	_
7-10	641-648	without	_	_	_	_
7-11	649-657	coronary	object[38]	new[38]	_	_
7-12	658-665	lesions	object[38]	new[38]	_	_
7-13	666-668	or	_	_	_	_
7-14	669-673	risk	abstract|abstract[40]	new|new[40]	coref	23-1[137_40]
7-15	674-681	factors	abstract[40]	new[40]	_	_
7-16	682-683	.	_	_	_	_

#Text=Patients with type I Kounis syndrome present electrocardiographic change with or without cardiac enzymes elevation due to the acute release of inflammatory mediators inducing coronary spasm .
8-1	684-692	Patients	person[41]	new[41]	coref	11-7[63_41]
8-2	693-697	with	person[41]	new[41]	_	_
8-3	698-702	type	person[41]|abstract[42]|abstract[43]	new[41]|giv[42]|giv[43]	coref|coref	9-2[50_42]|15-11[98_43]
8-4	703-704	I	person[41]|abstract[42]|abstract[43]	new[41]|giv[42]|giv[43]	_	_
8-5	705-711	Kounis	person[41]|abstract[43]	new[41]|giv[43]	_	_
8-6	712-720	syndrome	person[41]|abstract[43]	new[41]|giv[43]	_	_
8-7	721-728	present	_	_	_	_
8-8	729-749	electrocardiographic	event[44]	new[44]	_	_
8-9	750-756	change	event[44]	new[44]	_	_
8-10	757-761	with	_	_	_	_
8-11	762-764	or	_	_	_	_
8-12	765-772	without	_	_	_	_
8-13	773-780	cardiac	abstract[45]|abstract[46]	new[45]|new[46]	_	_
8-14	781-788	enzymes	abstract[45]|abstract[46]	new[45]|new[46]	_	_
8-15	789-798	elevation	abstract[46]	new[46]	_	_
8-16	799-802	due	abstract[46]	new[46]	_	_
8-17	803-805	to	abstract[46]	new[46]	_	_
8-18	806-809	the	abstract[46]|event[47]	new[46]|new[47]	_	_
8-19	810-815	acute	abstract[46]|event[47]	new[46]|new[47]	_	_
8-20	816-823	release	abstract[46]|event[47]	new[46]|new[47]	_	_
8-21	824-826	of	abstract[46]|event[47]	new[46]|new[47]	_	_
8-22	827-839	inflammatory	abstract[46]|event[47]|person[48]	new[46]|new[47]|new[48]	coref	10-10[55_48]
8-23	840-849	mediators	abstract[46]|event[47]|person[48]	new[46]|new[47]|new[48]	_	_
8-24	850-858	inducing	abstract[46]|event[47]|person[48]	new[46]|new[47]|new[48]	_	_
8-25	859-867	coronary	abstract[46]|event[47]|person[48]|event[49]	new[46]|new[47]|new[48]|giv[49]	_	_
8-26	868-873	spasm	abstract[46]|event[47]|person[48]|event[49]	new[46]|new[47]|new[48]|giv[49]	_	_
8-27	874-875	.	_	_	_	_

#Text=The type II variant includes pre-existing atheromatous disease .
9-1	876-879	The	abstract[51]	giv[51]	_	_
9-2	880-884	type	abstract[50]|abstract[51]	giv[50]|giv[51]	coref	11-1[0_50]
9-3	885-887	II	abstract[50]|abstract[51]	giv[50]|giv[51]	_	_
9-4	888-895	variant	abstract[51]	giv[51]	_	_
9-5	896-904	includes	_	_	_	_
9-6	905-917	pre-existing	abstract[52]	new[52]	coref	11-9[64_52]
9-7	918-930	atheromatous	abstract[52]	new[52]	_	_
9-8	931-938	disease	abstract[52]	new[52]	_	_
9-9	939-940	.	_	_	_	_

#Text=An acute allergic reaction leading to the release of inflammatory mediators induces plaque erosion or rupture , which causes acute myocardial infarction .
10-1	941-943	An	event[53]	giv[53]	coref	22-14[129_53]
10-2	944-949	acute	event[53]	giv[53]	_	_
10-3	950-958	allergic	event[53]	giv[53]	_	_
10-4	959-967	reaction	event[53]	giv[53]	_	_
10-5	968-975	leading	event[53]	giv[53]	_	_
10-6	976-978	to	event[53]	giv[53]	_	_
10-7	979-982	the	event[53]|event[54]	giv[53]|new[54]	_	_
10-8	983-990	release	event[53]|event[54]	giv[53]|new[54]	_	_
10-9	991-993	of	event[53]|event[54]	giv[53]|new[54]	_	_
10-10	994-1006	inflammatory	event[53]|event[54]|person[55]	giv[53]|new[54]|giv[55]	coref	20-12[112_55]
10-11	1007-1016	mediators	event[53]|event[54]|person[55]	giv[53]|new[54]|giv[55]	_	_
10-12	1017-1024	induces	_	_	_	_
10-13	1025-1031	plaque	object|event[57]|event[58]	new|new[57]|new[58]	coref|coref|coref	24-5|24-5[145_57]|24-5[146_58]
10-14	1032-1039	erosion	event[57]|event[58]	new[57]|new[58]	_	_
10-15	1040-1042	or	event[58]	new[58]	_	_
10-16	1043-1050	rupture	event[58]|event[59]	new[58]|new[59]	coref	24-8[0_59]
10-17	1051-1052	,	event[58]|event[59]	new[58]|new[59]	_	_
10-18	1053-1058	which	event[58]|event[59]	new[58]|new[59]	_	_
10-19	1059-1065	causes	event[58]|event[59]	new[58]|new[59]	_	_
10-20	1066-1071	acute	event[58]|event[59]|event[60]	new[58]|new[59]|new[60]	_	_
10-21	1072-1082	myocardial	event[58]|event[59]|event[60]	new[58]|new[59]|new[60]	_	_
10-22	1083-1093	infarction	event[58]|event[59]|event[60]	new[58]|new[59]|new[60]	_	_
10-23	1094-1095	.	_	_	_	_

#Text=Type III has been defined in patients with pre-existing coronary disease and coronary artery stent thrombosis .
11-1	1096-1100	Type	abstract	giv	_	_
11-2	1101-1104	III	abstract	new	_	_
11-3	1105-1108	has	_	_	_	_
11-4	1109-1113	been	_	_	_	_
11-5	1114-1121	defined	_	_	_	_
11-6	1122-1124	in	_	_	_	_
11-7	1125-1133	patients	person[63]	giv[63]	coref	12-20[76_63]
11-8	1134-1138	with	person[63]	giv[63]	_	_
11-9	1139-1151	pre-existing	person[63]|abstract[64]	giv[63]|giv[64]	_	_
11-10	1152-1160	coronary	person[63]|abstract[64]	giv[63]|giv[64]	_	_
11-11	1161-1168	disease	person[63]|abstract[64]	giv[63]|giv[64]	_	_
11-12	1169-1172	and	person[63]	giv[63]	_	_
11-13	1173-1181	coronary	person[63]|object[67]	giv[63]|new[67]	coref	12-13[75_67]
11-14	1182-1188	artery	person[63]|object|object[67]	giv[63]|new|new[67]	_	_
11-15	1189-1194	stent	person[63]|abstract|object[67]	giv[63]|new|new[67]	coref	12-13[73_0]
11-16	1195-1205	thrombosis	person[63]|object[67]	giv[63]|new[67]	_	_
11-17	1206-1207	.	_	_	_	_

#Text=In the Jack P. Chen et al. study , the pathology of drug-eluting stent ( DES ) thrombosis in these patients presented with eosinophils and mast cell infiltration in Giemsa and hematoxylin – eosin staining .
12-1	1208-1210	In	_	_	_	_
12-2	1211-1214	the	abstract[71]	giv[71]	coref	13-2[84_71]
12-3	1215-1219	Jack	person[68]|abstract[71]	new[68]|giv[71]	_	_
12-4	1220-1222	P.	person[68]|abstract[71]	new[68]|giv[71]	_	_
12-5	1223-1227	Chen	person|abstract[71]	new|giv[71]	_	_
12-6	1228-1230	et	abstract[71]	giv[71]	_	_
12-7	1231-1234	al.	abstract|abstract[71]	new|giv[71]	coref	13-6
12-8	1235-1240	study	abstract[71]	giv[71]	_	_
12-9	1241-1242	,	_	_	_	_
12-10	1243-1246	the	abstract[72]	new[72]	_	_
12-11	1247-1256	pathology	abstract[72]	new[72]	_	_
12-12	1257-1259	of	abstract[72]	new[72]	_	_
12-13	1260-1272	drug-eluting	abstract[72]|abstract[73]|object[75]	new[72]|giv[73]|giv[75]	appos|coref	12-16[0_73]|13-12[87_75]
12-14	1273-1278	stent	abstract[72]|abstract[73]|object[75]	new[72]|giv[73]|giv[75]	_	_
12-15	1279-1280	(	abstract[72]|object[75]	new[72]|giv[75]	_	_
12-16	1281-1284	DES	abstract[72]|abstract|object[75]	new[72]|giv|giv[75]	coref	13-13
12-17	1285-1286	)	abstract[72]|object[75]	new[72]|giv[75]	_	_
12-18	1287-1297	thrombosis	abstract[72]|object[75]	new[72]|giv[75]	_	_
12-19	1298-1300	in	abstract[72]|object[75]	new[72]|giv[75]	_	_
12-20	1301-1306	these	abstract[72]|object[75]|person[76]	new[72]|giv[75]|giv[76]	coref	30-10[171_76]
12-21	1307-1315	patients	abstract[72]|object[75]|person[76]	new[72]|giv[75]|giv[76]	_	_
12-22	1316-1325	presented	_	_	_	_
12-23	1326-1330	with	_	_	_	_
12-24	1331-1342	eosinophils	substance	new	_	_
12-25	1343-1346	and	_	_	_	_
12-26	1347-1351	mast	object[78]|abstract[79]	new[78]|new[79]	coref	19-11[105_78]
12-27	1352-1356	cell	object[78]|abstract[79]	new[78]|new[79]	_	_
12-28	1357-1369	infiltration	abstract[79]	new[79]	_	_
12-29	1370-1372	in	abstract[79]	new[79]	_	_
12-30	1373-1379	Giemsa	abstract[79]|place	new[79]|new	_	_
12-31	1380-1383	and	_	_	_	_
12-32	1384-1395	hematoxylin	abstract[81]	new[81]	_	_
12-33	1396-1397	–	abstract[81]	new[81]	_	_
12-34	1398-1403	eosin	abstract[81]	new[81]	_	_
12-35	1404-1412	staining	abstract[81]	new[81]	_	_
12-36	1413-1414	.	_	_	_	_

#Text=In the Stéphane Cook et al. study , the association with late DES thrombosis and local inflammation in histopathology was reported .
13-1	1415-1417	In	_	_	_	_
13-2	1418-1421	the	abstract[84]	giv[84]	_	_
13-3	1422-1430	Stéphane	person|abstract[84]	new|giv[84]	_	_
13-4	1431-1435	Cook	abstract[84]	giv[84]	_	_
13-5	1436-1438	et	abstract[84]	giv[84]	_	_
13-6	1439-1442	al.	abstract|abstract[84]	giv|giv[84]	_	_
13-7	1443-1448	study	abstract[84]	giv[84]	_	_
13-8	1449-1450	,	_	_	_	_
13-9	1451-1454	the	abstract[85]	new[85]	_	_
13-10	1455-1466	association	abstract[85]	new[85]	_	_
13-11	1467-1471	with	abstract[85]	new[85]	_	_
13-12	1472-1476	late	abstract[85]|object[87]	new[85]|giv[87]	coref	15-1[95_87]
13-13	1477-1480	DES	abstract[85]|abstract|object[87]	new[85]|giv|giv[87]	coref	15-3
13-14	1481-1491	thrombosis	abstract[85]|object[87]	new[85]|giv[87]	_	_
13-15	1492-1495	and	abstract[85]	new[85]	_	_
13-16	1496-1501	local	abstract[85]|abstract[88]	new[85]|new[88]	_	_
13-17	1502-1514	inflammation	abstract[85]|abstract[88]	new[85]|new[88]	_	_
13-18	1515-1517	in	abstract[85]	new[85]	_	_
13-19	1518-1532	histopathology	abstract[85]|person	new[85]|new	_	_
13-20	1533-1536	was	_	_	_	_
13-21	1537-1545	reported	_	_	_	_
13-22	1546-1547	.	_	_	_	_

#Text=In intravascular ultrasound analysis , vessel remodeling was also confirmed .
14-1	1548-1550	In	_	_	_	_
14-2	1551-1564	intravascular	abstract[91]	new[91]	_	_
14-3	1565-1575	ultrasound	abstract|abstract[91]	new|new[91]	_	_
14-4	1576-1584	analysis	abstract[91]	new[91]	_	_
14-5	1585-1586	,	_	_	_	_
14-6	1587-1593	vessel	object|event[93]	new|new[93]	_	_
14-7	1594-1604	remodeling	event[93]	new[93]	_	_
14-8	1605-1608	was	_	_	_	_
14-9	1609-1613	also	_	_	_	_
14-10	1614-1623	confirmed	_	_	_	_
14-11	1624-1625	.	_	_	_	_

#Text=Very late stent thrombosis is recognized as a feature of Kounis syndrome (
15-1	1626-1630	Very	object[95]	giv[95]	_	_
15-2	1631-1635	late	object[95]	giv[95]	_	_
15-3	1636-1641	stent	abstract|object[95]	giv|giv[95]	_	_
15-4	1642-1652	thrombosis	object[95]	giv[95]	_	_
15-5	1653-1655	is	_	_	_	_
15-6	1656-1666	recognized	_	_	_	_
15-7	1667-1669	as	_	_	_	_
15-8	1670-1671	a	abstract[96]	new[96]	_	_
15-9	1672-1679	feature	abstract[96]	new[96]	_	_
15-10	1680-1682	of	abstract[96]	new[96]	_	_
15-11	1683-1689	Kounis	abstract[96]|person|abstract[98]	new[96]|giv|giv[98]	coref|coref	19-6|19-6[104_98]
15-12	1690-1698	syndrome	abstract[96]|abstract[98]	new[96]|giv[98]	_	_
15-13	1699-1700	(	_	_	_	_

#Text=Figure 5
16-1	1701-1707	Figure	abstract[99]	new[99]	coref	28-1[167_99]
16-2	1708-1709	5	abstract[99]	new[99]	_	_

#Text=) .
17-1	1710-1711	)	_	_	_	_
17-2	1712-1713	.	_	_	_	_

#Text=The detail pathophysiological mechanisms remain elusive .
18-1	1714-1717	The	abstract[101]	new[101]	_	_
18-2	1718-1724	detail	abstract|abstract[101]	new|new[101]	_	_
18-3	1725-1743	pathophysiological	abstract[101]	new[101]	_	_
18-4	1744-1754	mechanisms	abstract[101]	new[101]	_	_
18-5	1755-1761	remain	_	_	_	_
18-6	1762-1769	elusive	_	_	_	_
18-7	1770-1771	.	_	_	_	_

#Text=In the current concept , Kounis syndrome is related to inflammatory cell and mast cell-associated disorders .
19-1	1772-1774	In	_	_	_	_
19-2	1775-1778	the	abstract[102]	giv[102]	coref	38-2[231_102]
19-3	1779-1786	current	abstract[102]	giv[102]	_	_
19-4	1787-1794	concept	abstract[102]	giv[102]	_	_
19-5	1795-1796	,	_	_	_	_
19-6	1797-1803	Kounis	person|abstract[104]	giv|giv[104]	coref|coref	21-5|21-10[118_104]
19-7	1804-1812	syndrome	abstract[104]	giv[104]	_	_
19-8	1813-1815	is	_	_	_	_
19-9	1816-1823	related	_	_	_	_
19-10	1824-1826	to	_	_	_	_
19-11	1827-1839	inflammatory	object[105]	giv[105]	coref	20-2[107_105]
19-12	1840-1844	cell	object[105]	giv[105]	_	_
19-13	1845-1848	and	_	_	_	_
19-14	1849-1853	mast	abstract[106]	new[106]	coref	31-15[180_106]
19-15	1854-1869	cell-associated	abstract[106]	new[106]	_	_
19-16	1870-1879	disorders	abstract[106]	new[106]	_	_
19-17	1880-1881	.	_	_	_	_

#Text=Local inflammatory cell interactions induce hypersensitivity and anaphylactic results by releasing inflammatory mediators after activation .
20-1	1882-1887	Local	abstract[108]	new[108]	_	_
20-2	1888-1900	inflammatory	object[107]|abstract[108]	giv[107]|new[108]	_	_
20-3	1901-1905	cell	object[107]|abstract[108]	giv[107]|new[108]	_	_
20-4	1906-1918	interactions	abstract[108]	new[108]	_	_
20-5	1919-1925	induce	_	_	_	_
20-6	1926-1942	hypersensitivity	abstract|abstract[110]	giv|giv[110]	coref	21-21
20-7	1943-1946	and	abstract[110]	giv[110]	_	_
20-8	1947-1959	anaphylactic	abstract[110]|abstract[111]	giv[110]|new[111]	coref	34-1[209_111]
20-9	1960-1967	results	abstract[110]|abstract[111]	giv[110]|new[111]	_	_
20-10	1968-1970	by	_	_	_	_
20-11	1971-1980	releasing	_	_	_	_
20-12	1981-1993	inflammatory	person[112]	giv[112]	coref	22-10[128_112]
20-13	1994-2003	mediators	person[112]	giv[112]	_	_
20-14	2004-2009	after	_	_	_	_
20-15	2010-2020	activation	event	new	_	_
20-16	2021-2022	.	_	_	_	_

#Text=In the Nicholas G. Kounis et al. summary , Kounis syndrome is a complex multisystem disease accompanied by allergy – hypersensitivity – anaphylaxis .
21-1	2023-2025	In	_	_	_	_
21-2	2026-2029	the	abstract[116]	new[116]	_	_
21-3	2030-2038	Nicholas	person[114]|abstract[116]	new[114]|new[116]	_	_
21-4	2039-2041	G.	person[114]|abstract[116]	new[114]|new[116]	_	_
21-5	2042-2048	Kounis	person|abstract[116]	giv|new[116]	coref	21-10
21-6	2049-2051	et	abstract[116]	new[116]	_	_
21-7	2052-2055	al.	abstract[116]	new[116]	_	_
21-8	2056-2063	summary	abstract[116]	new[116]	_	_
21-9	2064-2065	,	_	_	_	_
21-10	2066-2072	Kounis	person|abstract[118]	giv|giv[118]	coref|coref	21-13[120_118]|26-4
21-11	2073-2081	syndrome	abstract[118]	giv[118]	_	_
21-12	2082-2084	is	_	_	_	_
21-13	2085-2086	a	abstract[120]	giv[120]	coref	26-4[156_120]
21-14	2087-2094	complex	abstract[120]	giv[120]	_	_
21-15	2095-2106	multisystem	object|abstract[120]	new|giv[120]	_	_
21-16	2107-2114	disease	abstract[120]	giv[120]	_	_
21-17	2115-2126	accompanied	abstract[120]	giv[120]	_	_
21-18	2127-2129	by	abstract[120]	giv[120]	_	_
21-19	2130-2137	allergy	abstract[120]|abstract	giv[120]|new	coref	38-14
21-20	2138-2139	–	abstract[120]	giv[120]	_	_
21-21	2140-2156	hypersensitivity	abstract[120]|abstract	giv[120]|giv	coref	22-2
21-22	2157-2158	–	abstract[120]	giv[120]	_	_
21-23	2159-2170	anaphylaxis	abstract[120]|abstract	giv[120]|new	_	_
21-24	2171-2172	.	_	_	_	_

#Text=During hypersensitivity , the mast cells and lymphocytes release inflammatory mediators , promoting an allergic reaction via a high serum level of histamine , proteases , arachidonic acid products , and chemokines .
22-1	2173-2179	During	_	_	_	_
22-2	2180-2196	hypersensitivity	abstract	giv	_	_
22-3	2197-2198	,	_	_	_	_
22-4	2199-2202	the	plant[126]	new[126]	_	_
22-5	2203-2207	mast	object|plant[126]	new|new[126]	_	_
22-6	2208-2213	cells	plant[126]	new[126]	_	_
22-7	2214-2217	and	_	_	_	_
22-8	2218-2229	lymphocytes	organization	new	_	_
22-9	2230-2237	release	_	_	_	_
22-10	2238-2250	inflammatory	person[128]	giv[128]	coref	25-1[151_128]
22-11	2251-2260	mediators	person[128]	giv[128]	_	_
22-12	2261-2262	,	_	_	_	_
22-13	2263-2272	promoting	_	_	_	_
22-14	2273-2275	an	event[129]	giv[129]	coref	27-13[166_129]
22-15	2276-2284	allergic	event[129]	giv[129]	_	_
22-16	2285-2293	reaction	event[129]	giv[129]	_	_
22-17	2294-2297	via	_	_	_	_
22-18	2298-2299	a	abstract[131]	new[131]	_	_
22-19	2300-2304	high	abstract[131]	new[131]	_	_
22-20	2305-2310	serum	substance|abstract[131]	new|new[131]	coref	27-2
22-21	2311-2316	level	abstract[131]	new[131]	_	_
22-22	2317-2319	of	abstract[131]	new[131]	_	_
22-23	2320-2329	histamine	abstract[131]|animal	new[131]|new	coref	27-7
22-24	2330-2331	,	abstract[131]	new[131]	_	_
22-25	2332-2341	proteases	abstract[131]|abstract	new[131]|new	coref	24-1[143_0]
22-26	2342-2343	,	abstract[131]	new[131]	_	_
22-27	2344-2355	arachidonic	abstract[131]|substance[134]|substance[135]	new[131]|new[134]|new[135]	coref	32-18[192_134]
22-28	2356-2360	acid	abstract[131]|substance[134]|substance[135]	new[131]|new[134]|new[135]	_	_
22-29	2361-2369	products	abstract[131]|substance[135]	new[131]|new[135]	_	_
22-30	2370-2371	,	abstract[131]	new[131]	_	_
22-31	2372-2375	and	abstract[131]	new[131]	_	_
22-32	2376-2386	chemokines	abstract[131]|abstract	new[131]|new	_	_
22-33	2387-2388	.	_	_	_	_

#Text=These factors cause platelet aggregating and tissue factor expression .
23-1	2389-2394	These	abstract[137]	giv[137]	_	_
23-2	2395-2402	factors	abstract[137]	giv[137]	_	_
23-3	2403-2408	cause	_	_	_	_
23-4	2409-2417	platelet	object|abstract[139]	new|new[139]	_	_
23-5	2418-2429	aggregating	abstract[139]	new[139]	_	_
23-6	2430-2433	and	_	_	_	_
23-7	2434-2440	tissue	object|abstract[141]|abstract[142]	new|new[141]|new[142]	_	_
23-8	2441-2447	factor	abstract[141]|abstract[142]	new[141]|new[142]	_	_
23-9	2448-2458	expression	abstract[142]	new[142]	_	_
23-10	2459-2460	.	_	_	_	_

#Text=The proteases also induce plaque erosion and rupture by activating matrix metalloproteinase ( MMP ) .
24-1	2461-2464	The	abstract[143]	giv[143]	_	_
24-2	2465-2474	proteases	abstract[143]	giv[143]	_	_
24-3	2475-2479	also	_	_	_	_
24-4	2480-2486	induce	_	_	_	_
24-5	2487-2493	plaque	object|event[145]|event[146]	giv|giv[145]|giv[146]	_	_
24-6	2494-2501	erosion	event[145]|event[146]	giv[145]|giv[146]	_	_
24-7	2502-2505	and	event[146]	giv[146]	_	_
24-8	2506-2513	rupture	event[146]|event	giv[146]|giv	_	_
24-9	2514-2516	by	_	_	_	_
24-10	2517-2527	activating	_	_	_	_
24-11	2528-2534	matrix	abstract|substance[149]	new|new[149]	_	_
24-12	2535-2552	metalloproteinase	substance[149]	new[149]	_	_
24-13	2553-2554	(	_	_	_	_
24-14	2555-2558	MMP	abstract	new	_	_
24-15	2559-2560	)	_	_	_	_
24-16	2561-2562	.	_	_	_	_

#Text=The downstream mediators induce vasoconstriction and worsen coronary vasospasm .
25-1	2563-2566	The	person[151]	giv[151]	_	_
25-2	2567-2577	downstream	person[151]	giv[151]	_	_
25-3	2578-2587	mediators	person[151]	giv[151]	_	_
25-4	2588-2594	induce	_	_	_	_
25-5	2595-2611	vasoconstriction	event	new	_	_
25-6	2612-2615	and	_	_	_	_
25-7	2616-2622	worsen	_	_	_	_
25-8	2623-2631	coronary	event[153]	new[153]	coref	41-8[256_153]
25-9	2632-2641	vasospasm	event[153]	new[153]	_	_
25-10	2642-2643	.	_	_	_	_

#Text=The diagnosis of Kounis syndrome is based on clinical symptoms and cardiac surveys , including cardiac enzyme , electrocardiographic , echocardiographic , and angiography .
26-1	2644-2647	The	abstract[154]	new[154]	_	_
26-2	2648-2657	diagnosis	abstract[154]	new[154]	_	_
26-3	2658-2660	of	abstract[154]	new[154]	_	_
26-4	2661-2667	Kounis	abstract[154]|person|abstract[156]	new[154]|giv|giv[156]	coref|coref	30-18|30-18[173_156]
26-5	2668-2676	syndrome	abstract[154]|abstract[156]	new[154]|giv[156]	_	_
26-6	2677-2679	is	_	_	_	_
26-7	2680-2685	based	_	_	_	_
26-8	2686-2688	on	_	_	_	_
26-9	2689-2697	clinical	abstract[157]	new[157]	_	_
26-10	2698-2706	symptoms	abstract[157]	new[157]	_	_
26-11	2707-2710	and	_	_	_	_
26-12	2711-2718	cardiac	abstract[158]	new[158]	_	_
26-13	2719-2726	surveys	abstract[158]	new[158]	_	_
26-14	2727-2728	,	abstract[158]	new[158]	_	_
26-15	2729-2738	including	abstract[158]	new[158]	_	_
26-16	2739-2746	cardiac	abstract[158]|abstract[159]	new[158]|new[159]	_	_
26-17	2747-2753	enzyme	abstract[158]|abstract[159]	new[158]|new[159]	_	_
26-18	2754-2755	,	abstract[158]	new[158]	_	_
26-19	2756-2776	electrocardiographic	abstract[158]	new[158]	_	_
26-20	2777-2778	,	abstract[158]	new[158]	_	_
26-21	2779-2796	echocardiographic	abstract[158]	new[158]	_	_
26-22	2797-2798	,	abstract[158]	new[158]	_	_
26-23	2799-2802	and	abstract[158]	new[158]	_	_
26-24	2803-2814	angiography	abstract[158]|abstract	new[158]|new	coref	31-3[176_0]
26-25	2815-2816	.	_	_	_	_

#Text=The serum level of tryptase and histamine can provide more information about the allergic reaction (
27-1	2817-2820	The	abstract[162]	new[162]	_	_
27-2	2821-2826	serum	substance|abstract[162]	giv|new[162]	_	_
27-3	2827-2832	level	abstract[162]	new[162]	_	_
27-4	2833-2835	of	abstract[162]	new[162]	_	_
27-5	2836-2844	tryptase	abstract[162]|substance	new[162]|new	_	_
27-6	2845-2848	and	abstract[162]	new[162]	_	_
27-7	2849-2858	histamine	abstract[162]|animal	new[162]|giv	_	_
27-8	2859-2862	can	_	_	_	_
27-9	2863-2870	provide	_	_	_	_
27-10	2871-2875	more	abstract[165]	new[165]	coref	31-7[177_165]
27-11	2876-2887	information	abstract[165]	new[165]	_	_
27-12	2888-2893	about	abstract[165]	new[165]	_	_
27-13	2894-2897	the	abstract[165]|event[166]	new[165]|giv[166]	coref	30-11[170_166]
27-14	2898-2906	allergic	abstract[165]|event[166]	new[165]|giv[166]	_	_
27-15	2907-2915	reaction	abstract[165]|event[166]	new[165]|giv[166]	_	_
27-16	2916-2917	(	_	_	_	_

#Text=Figure 5
28-1	2918-2924	Figure	abstract[167]	giv[167]	coref	53-1[315_167]
28-2	2925-2926	5	abstract[167]	giv[167]	_	_

#Text=) .
29-1	2927-2928	)	_	_	_	_
29-2	2929-2930	.	_	_	_	_

#Text=Tajda Keber et al. suggested measuring cardiac enzymes in acute allergic reaction patients as necessary to diagnose Kounis syndrome promptly and manage cardiac injury early and appropriately .
30-1	2931-2936	Tajda	person[168]	new[168]	_	_
30-2	2937-2942	Keber	person[168]	new[168]	_	_
30-3	2943-2945	et	_	_	_	_
30-4	2946-2949	al.	_	_	_	_
30-5	2950-2959	suggested	_	_	_	_
30-6	2960-2969	measuring	_	_	_	_
30-7	2970-2977	cardiac	abstract[169]	new[169]	_	_
30-8	2978-2985	enzymes	abstract[169]	new[169]	_	_
30-9	2986-2988	in	_	_	_	_
30-10	2989-2994	acute	person[171]	giv[171]	coref	31-19[184_171]
30-11	2995-3003	allergic	event[170]|person[171]	giv[170]|giv[171]	coref	36-23[228_170]
30-12	3004-3012	reaction	event[170]|person[171]	giv[170]|giv[171]	_	_
30-13	3013-3021	patients	person[171]	giv[171]	_	_
30-14	3022-3024	as	_	_	_	_
30-15	3025-3034	necessary	_	_	_	_
30-16	3035-3037	to	_	_	_	_
30-17	3038-3046	diagnose	_	_	_	_
30-18	3047-3053	Kounis	person|abstract[173]	giv|giv[173]	coref|coref	32-30[195_173]|33-12
30-19	3054-3062	syndrome	abstract[173]	giv[173]	_	_
30-20	3063-3071	promptly	_	_	_	_
30-21	3072-3075	and	_	_	_	_
30-22	3076-3082	manage	_	_	_	_
30-23	3083-3090	cardiac	event[174]	new[174]	coref	35-10[219_174]
30-24	3091-3097	injury	event[174]	new[174]	_	_
30-25	3098-3103	early	_	_	_	_
30-26	3104-3107	and	_	_	_	_
30-27	3108-3121	appropriately	_	_	_	_
30-28	3122-3123	.	_	_	_	_

#Text=Echocardiography and coronary angiography can provide detailed information to rule out takotsubo cardiomyopathy or other cardiac disorders in cardiac wall motion abnormalities patients .
31-1	3124-3140	Echocardiography	abstract	new	_	_
31-2	3141-3144	and	_	_	_	_
31-3	3145-3153	coronary	abstract[176]	giv[176]	_	_
31-4	3154-3165	angiography	abstract[176]	giv[176]	_	_
31-5	3166-3169	can	_	_	_	_
31-6	3170-3177	provide	_	_	_	_
31-7	3178-3186	detailed	abstract[177]	giv[177]	_	_
31-8	3187-3198	information	abstract[177]	giv[177]	_	_
31-9	3199-3201	to	_	_	_	_
31-10	3202-3206	rule	_	_	_	_
31-11	3207-3210	out	_	_	_	_
31-12	3211-3220	takotsubo	animal|abstract[179]	new|new[179]	_	_
31-13	3221-3235	cardiomyopathy	abstract[179]	new[179]	_	_
31-14	3236-3238	or	_	_	_	_
31-15	3239-3244	other	abstract[180]	giv[180]	_	_
31-16	3245-3252	cardiac	abstract[180]	giv[180]	_	_
31-17	3253-3262	disorders	abstract[180]	giv[180]	_	_
31-18	3263-3265	in	abstract[180]	giv[180]	_	_
31-19	3266-3273	cardiac	abstract[180]|abstract[183]|person[184]	giv[180]|new[183]|giv[184]	ana	32-35[0_184]
31-20	3274-3278	wall	abstract[180]|object|abstract[182]|abstract[183]|person[184]	giv[180]|new|new[182]|new[183]|giv[184]	_	_
31-21	3279-3285	motion	abstract[180]|abstract[182]|abstract[183]|person[184]	giv[180]|new[182]|new[183]|giv[184]	_	_
31-22	3286-3299	abnormalities	abstract[180]|abstract[183]|person[184]	giv[180]|new[183]|giv[184]	_	_
31-23	3300-3308	patients	abstract[180]|person[184]	giv[180]|giv[184]	_	_
31-24	3309-3310	.	_	_	_	_

#Text=Keita Goto et al. reported that thallium-201 ( Tl ) single-photon emission CT ( SPECT ) and 125I-15-(p-iodophenyl)-3-(R , S)-methylpentadecanoic acid ( BMIPP ) SPECT were conducted in a post-Kounis syndrome patient , and they revealed a local perfusion defect with decreased BMIPP uptake .
32-1	3311-3316	Keita	person[185]	new[185]	_	_
32-2	3317-3321	Goto	person[185]	new[185]	_	_
32-3	3322-3324	et	abstract	new	_	_
32-4	3325-3328	al.	_	_	_	_
32-5	3329-3337	reported	_	_	_	_
32-6	3338-3342	that	_	_	_	_
32-7	3343-3355	thallium-201	abstract|abstract[189]|abstract[190]	new|new[189]|new[190]	appos|appos	32-9|32-15[0_190]
32-8	3356-3357	(	abstract[189]|abstract[190]	new[189]|new[190]	_	_
32-9	3358-3360	Tl	abstract|abstract[189]|abstract[190]	giv|new[189]|new[190]	_	_
32-10	3361-3362	)	abstract[189]|abstract[190]	new[189]|new[190]	_	_
32-11	3363-3376	single-photon	abstract[189]|abstract[190]	new[189]|new[190]	_	_
32-12	3377-3385	emission	abstract[189]|abstract[190]	new[189]|new[190]	_	_
32-13	3386-3388	CT	abstract[190]	new[190]	_	_
32-14	3389-3390	(	_	_	_	_
32-15	3391-3396	SPECT	abstract	giv	coref	32-25
32-16	3397-3398	)	_	_	_	_
32-17	3399-3402	and	_	_	_	_
32-18	3403-3430	125I-15-(p-iodophenyl)-3-(R	substance[192]	giv[192]	coref	40-14[248_192]
32-19	3431-3432	,	substance[192]	giv[192]	_	_
32-20	3433-3455	S)-methylpentadecanoic	substance[192]	giv[192]	_	_
32-21	3456-3460	acid	substance[192]	giv[192]	_	_
32-22	3461-3462	(	_	_	_	_
32-23	3463-3468	BMIPP	abstract	new	coref	32-43
32-24	3469-3470	)	_	_	_	_
32-25	3471-3476	SPECT	abstract	giv	_	_
32-26	3477-3481	were	_	_	_	_
32-27	3482-3491	conducted	_	_	_	_
32-28	3492-3494	in	_	_	_	_
32-29	3495-3496	a	person[196]	new[196]	_	_
32-30	3497-3508	post-Kounis	abstract[195]|person[196]	giv[195]|new[196]	coref	33-9[206_195]
32-31	3509-3517	syndrome	abstract[195]|person[196]	giv[195]|new[196]	_	_
32-32	3518-3525	patient	person[196]	new[196]	_	_
32-33	3526-3527	,	_	_	_	_
32-34	3528-3531	and	_	_	_	_
32-35	3532-3536	they	person	giv	coref	33-6[204_0]
32-36	3537-3545	revealed	_	_	_	_
32-37	3546-3547	a	abstract[199]	new[199]	coref	34-4[211_199]
32-38	3548-3553	local	abstract[199]	new[199]	_	_
32-39	3554-3563	perfusion	abstract|abstract[199]	new|new[199]	_	_
32-40	3564-3570	defect	abstract[199]	new[199]	_	_
32-41	3571-3575	with	abstract[199]	new[199]	_	_
32-42	3576-3585	decreased	abstract[199]|abstract[201]	new[199]|new[201]	_	_
32-43	3586-3591	BMIPP	abstract[199]|abstract|abstract[201]	new[199]|giv|new[201]	_	_
32-44	3592-3598	uptake	abstract[199]|abstract[201]	new[199]|new[201]	_	_
32-45	3599-3600	.	_	_	_	_

#Text=Aylin Okur et al. included 26 patients with known or suspected Kounis syndrome and conducted contrast-enhanced magnetic resonance imaging .
33-1	3601-3606	Aylin	person[202]	new[202]	_	_
33-2	3607-3611	Okur	person[202]	new[202]	_	_
33-3	3612-3614	et	_	_	_	_
33-4	3615-3618	al.	person	new	_	_
33-5	3619-3627	included	_	_	_	_
33-6	3628-3630	26	person[204]	giv[204]	coref	42-2[257_204]
33-7	3631-3639	patients	person[204]	giv[204]	_	_
33-8	3640-3644	with	person[204]	giv[204]	_	_
33-9	3645-3650	known	person[204]|abstract[206]	giv[204]|giv[206]	coref	35-13[221_206]
33-10	3651-3653	or	person[204]|abstract[206]	giv[204]|giv[206]	_	_
33-11	3654-3663	suspected	person[204]|abstract[206]	giv[204]|giv[206]	_	_
33-12	3664-3670	Kounis	person[204]|person|abstract[206]	giv[204]|giv|giv[206]	coref	35-13
33-13	3671-3679	syndrome	person[204]|abstract[206]	giv[204]|giv[206]	_	_
33-14	3680-3683	and	_	_	_	_
33-15	3684-3693	conducted	_	_	_	_
33-16	3694-3711	contrast-enhanced	abstract[208]	new[208]	_	_
33-17	3712-3720	magnetic	abstract[207]|abstract[208]	new[207]|new[208]	_	_
33-18	3721-3730	resonance	abstract[207]|abstract[208]	new[207]|new[208]	_	_
33-19	3731-3738	imaging	abstract[208]	new[208]	_	_
33-20	3739-3740	.	_	_	_	_

#Text=The results revealed an early-phase subendocardial contrast defect and local edema in lesion areas in T2-weighted images .
34-1	3741-3744	The	abstract[209]	giv[209]	_	_
34-2	3745-3752	results	abstract[209]	giv[209]	_	_
34-3	3753-3761	revealed	_	_	_	_
34-4	3762-3764	an	abstract[211]	giv[211]	_	_
34-5	3765-3776	early-phase	abstract[211]	giv[211]	_	_
34-6	3777-3791	subendocardial	abstract[211]	giv[211]	_	_
34-7	3792-3800	contrast	abstract|abstract[211]	new|giv[211]	_	_
34-8	3801-3807	defect	abstract[211]	giv[211]	_	_
34-9	3808-3811	and	_	_	_	_
34-10	3812-3817	local	abstract[212]	new[212]	_	_
34-11	3818-3823	edema	abstract[212]	new[212]	_	_
34-12	3824-3826	in	abstract[212]	new[212]	_	_
34-13	3827-3833	lesion	abstract[212]|abstract|place[214]	new[212]|new|new[214]	_	_
34-14	3834-3839	areas	abstract[212]|place[214]	new[212]|new[214]	_	_
34-15	3840-3842	in	abstract[212]|place[214]	new[212]|new[214]	_	_
34-16	3843-3854	T2-weighted	abstract[212]|place[214]|abstract|abstract[216]	new[212]|new[214]|new|new[216]	coref	35-1[217_216]
34-17	3855-3861	images	abstract[212]|place[214]|abstract[216]	new[212]|new[214]|new[216]	_	_
34-18	3862-3863	.	_	_	_	_

#Text=These newer images provide a reliable study to assess cardiac injury in Kounis syndrome .
35-1	3864-3869	These	abstract[217]	giv[217]	_	_
35-2	3870-3875	newer	abstract[217]	giv[217]	_	_
35-3	3876-3882	images	abstract[217]	giv[217]	_	_
35-4	3883-3890	provide	_	_	_	_
35-5	3891-3892	a	abstract[218]	new[218]	_	_
35-6	3893-3901	reliable	abstract[218]	new[218]	_	_
35-7	3902-3907	study	abstract[218]	new[218]	_	_
35-8	3908-3910	to	abstract[218]	new[218]	_	_
35-9	3911-3917	assess	abstract[218]	new[218]	_	_
35-10	3918-3925	cardiac	abstract[218]|event[219]	new[218]|giv[219]	coref	36-18[227_219]
35-11	3926-3932	injury	abstract[218]|event[219]	new[218]|giv[219]	_	_
35-12	3933-3935	in	abstract[218]	new[218]	_	_
35-13	3936-3942	Kounis	abstract[218]|person|abstract[221]	new[218]|giv|giv[221]	coref|coref	36-13|36-13[226_221]
35-14	3943-3951	syndrome	abstract[218]|abstract[221]	new[218]|giv[221]	_	_
35-15	3952-3953	.	_	_	_	_

#Text=Compared to the majority of ACS subjects , the therapeutic strategy of Kounis syndrome should focus on both the cardiac injury and allergic reaction .
36-1	3954-3962	Compared	_	_	_	_
36-2	3963-3965	to	_	_	_	_
36-3	3966-3969	the	animal[223]	new[223]	_	_
36-4	3970-3978	majority	animal[223]	new[223]	_	_
36-5	3979-3981	of	animal[223]	new[223]	_	_
36-6	3982-3985	ACS	abstract|animal[223]	new|new[223]	coref	50-10
36-7	3986-3994	subjects	animal[223]	new[223]	_	_
36-8	3995-3996	,	_	_	_	_
36-9	3997-4000	the	abstract[224]	new[224]	_	_
36-10	4001-4012	therapeutic	abstract[224]	new[224]	_	_
36-11	4013-4021	strategy	abstract[224]	new[224]	_	_
36-12	4022-4024	of	abstract[224]	new[224]	_	_
36-13	4025-4031	Kounis	abstract[224]|person|abstract[226]	new[224]|giv|giv[226]	coref|coref	49-10|49-10[293_226]
36-14	4032-4040	syndrome	abstract[224]|abstract[226]	new[224]|giv[226]	_	_
36-15	4041-4047	should	_	_	_	_
36-16	4048-4053	focus	_	_	_	_
36-17	4054-4056	on	_	_	_	_
36-18	4057-4061	both	event[227]	giv[227]	coref	38-18[236_227]
36-19	4062-4065	the	event[227]	giv[227]	_	_
36-20	4066-4073	cardiac	event[227]	giv[227]	_	_
36-21	4074-4080	injury	event[227]	giv[227]	_	_
36-22	4081-4084	and	_	_	_	_
36-23	4085-4093	allergic	event[228]	giv[228]	coref	38-13[235_228]
36-24	4094-4102	reaction	event[228]	giv[228]	_	_
36-25	4103-4104	.	_	_	_	_

#Text=Sometimes , the two different conditions may require opposing treatments .
37-1	4105-4114	Sometimes	_	_	_	_
37-2	4115-4116	,	_	_	_	_
37-3	4117-4120	the	abstract[229]	new[229]	_	_
37-4	4121-4124	two	abstract[229]	new[229]	_	_
37-5	4125-4134	different	abstract[229]	new[229]	_	_
37-6	4135-4145	conditions	abstract[229]	new[229]	_	_
37-7	4146-4149	may	_	_	_	_
37-8	4150-4157	require	_	_	_	_
37-9	4158-4166	opposing	abstract[230]	new[230]	_	_
37-10	4167-4177	treatments	abstract[230]	new[230]	_	_
37-11	4178-4179	.	_	_	_	_

#Text=In the current concept , the administration of medicine should avoid promoting an allergy reaction and aggravating the cardiac injury .
38-1	4180-4182	In	_	_	_	_
38-2	4183-4186	the	abstract[231]	giv[231]	_	_
38-3	4187-4194	current	abstract[231]	giv[231]	_	_
38-4	4195-4202	concept	abstract[231]	giv[231]	_	_
38-5	4203-4204	,	_	_	_	_
38-6	4205-4208	the	organization[232]	new[232]	_	_
38-7	4209-4223	administration	organization[232]	new[232]	_	_
38-8	4224-4226	of	organization[232]	new[232]	_	_
38-9	4227-4235	medicine	organization[232]|abstract	new[232]|new	_	_
38-10	4236-4242	should	_	_	_	_
38-11	4243-4248	avoid	_	_	_	_
38-12	4249-4258	promoting	_	_	_	_
38-13	4259-4261	an	event[235]	giv[235]	coref	39-26[244_235]
38-14	4262-4269	allergy	abstract|event[235]	giv|giv[235]	_	_
38-15	4270-4278	reaction	event[235]	giv[235]	_	_
38-16	4279-4282	and	_	_	_	_
38-17	4283-4294	aggravating	_	_	_	_
38-18	4295-4298	the	event[236]	giv[236]	_	_
38-19	4299-4306	cardiac	event[236]	giv[236]	_	_
38-20	4307-4313	injury	event[236]	giv[236]	_	_
38-21	4314-4315	.	_	_	_	_

#Text=Intravenous corticosteroids ( hydrocortisone : 1 – 2 mg/kg/day ) and antihistamine agents ( diphenhydramine : 1 – 2 mg/kg ) are useful to control the allergic reaction .
39-1	4316-4327	Intravenous	substance[237]	new[237]	appos	39-4[0_237]
39-2	4328-4343	corticosteroids	substance[237]	new[237]	_	_
39-3	4344-4345	(	_	_	_	_
39-4	4346-4360	hydrocortisone	substance	giv	coref	55-3
39-5	4361-4362	:	_	_	_	_
39-6	4363-4364	1	time[239]	new[239]	_	_
39-7	4365-4366	–	time[239]	new[239]	_	_
39-8	4367-4368	2	time[239]	new[239]	_	_
39-9	4369-4378	mg/kg/day	time[239]	new[239]	_	_
39-10	4379-4380	)	_	_	_	_
39-11	4381-4384	and	_	_	_	_
39-12	4385-4398	antihistamine	person|substance[241]	new|new[241]	appos	39-15[0_241]
39-13	4399-4405	agents	substance[241]	new[241]	_	_
39-14	4406-4407	(	_	_	_	_
39-15	4408-4423	diphenhydramine	substance	giv	appos	39-17[243_0]
39-16	4424-4425	:	_	_	_	_
39-17	4426-4427	1	substance[243]	giv[243]	_	_
39-18	4428-4429	–	substance[243]	giv[243]	_	_
39-19	4430-4431	2	substance[243]	giv[243]	_	_
39-20	4432-4437	mg/kg	substance[243]	giv[243]	_	_
39-21	4438-4439	)	_	_	_	_
39-22	4440-4443	are	_	_	_	_
39-23	4444-4450	useful	_	_	_	_
39-24	4451-4453	to	_	_	_	_
39-25	4454-4461	control	_	_	_	_
39-26	4462-4465	the	event[244]	giv[244]	_	_
39-27	4466-4474	allergic	event[244]	giv[244]	_	_
39-28	4475-4483	reaction	event[244]	giv[244]	_	_
39-29	4484-4485	.	_	_	_	_

#Text=Aspirin is , however , potentially detrimental because of cyclooxygenase inhibition , promoting arachidonic acid release into the leukotriene pathway .
40-1	4486-4493	Aspirin	substance	new	_	_
40-2	4494-4496	is	_	_	_	_
40-3	4497-4498	,	_	_	_	_
40-4	4499-4506	however	_	_	_	_
40-5	4507-4508	,	_	_	_	_
40-6	4509-4520	potentially	_	_	_	_
40-7	4521-4532	detrimental	_	_	_	_
40-8	4533-4540	because	_	_	_	_
40-9	4541-4543	of	_	_	_	_
40-10	4544-4558	cyclooxygenase	abstract|abstract[247]	new|new[247]	_	_
40-11	4559-4569	inhibition	abstract[247]	new[247]	_	_
40-12	4570-4571	,	_	_	_	_
40-13	4572-4581	promoting	_	_	_	_
40-14	4582-4593	arachidonic	substance[248]|event[249]	giv[248]|new[249]	coref	51-15[304_248]
40-15	4594-4598	acid	substance[248]|event[249]	giv[248]|new[249]	_	_
40-16	4599-4606	release	event[249]	new[249]	_	_
40-17	4607-4611	into	_	_	_	_
40-18	4612-4615	the	abstract[251]	new[251]	_	_
40-19	4616-4627	leukotriene	abstract|abstract[251]	new|new[251]	_	_
40-20	4628-4635	pathway	abstract[251]	new[251]	_	_
40-21	4636-4637	.	_	_	_	_

#Text=Calcium channel blockers and nitrates can relieve the vasospasm .
41-1	4638-4645	Calcium	place|place[253]|substance[254]	new|new[253]|new[254]	_	_
41-2	4646-4653	channel	place[253]|substance[254]	new[253]|new[254]	_	_
41-3	4654-4662	blockers	substance[254]	new[254]	_	_
41-4	4663-4666	and	_	_	_	_
41-5	4667-4675	nitrates	substance	new	coref	42-6
41-6	4676-4679	can	_	_	_	_
41-7	4680-4687	relieve	_	_	_	_
41-8	4688-4691	the	event[256]	giv[256]	coref	45-14[0_256]
41-9	4692-4701	vasospasm	event[256]	giv[256]	_	_
41-10	4702-4703	.	_	_	_	_

#Text=In hemodynamically unstable patients , nitrates may not be appropriate due to their hypotension properties .
42-1	4704-4706	In	_	_	_	_
42-2	4707-4722	hemodynamically	person[257]	giv[257]	ana	42-13[0_257]
42-3	4723-4731	unstable	person[257]	giv[257]	_	_
42-4	4732-4740	patients	person[257]	giv[257]	_	_
42-5	4741-4742	,	_	_	_	_
42-6	4743-4751	nitrates	substance	giv	_	_
42-7	4752-4755	may	_	_	_	_
42-8	4756-4759	not	_	_	_	_
42-9	4760-4762	be	_	_	_	_
42-10	4763-4774	appropriate	_	_	_	_
42-11	4775-4778	due	_	_	_	_
42-12	4779-4781	to	_	_	_	_
42-13	4782-4787	their	person|abstract[261]	giv|new[261]	coref	50-1[296_0]
42-14	4788-4799	hypotension	abstract|abstract[261]	new|new[261]	_	_
42-15	4800-4810	properties	abstract[261]	new[261]	_	_
42-16	4811-4812	.	_	_	_	_

#Text=Opioids may induce mast cell degeneration , which may worsen the anaphylaxis .
43-1	4813-4820	Opioids	abstract	new	_	_
43-2	4821-4824	may	_	_	_	_
43-3	4825-4831	induce	_	_	_	_
43-4	4832-4836	mast	object|object[264]|event[265]	new|new[264]|new[265]	coref|coref|coref	45-8[274_265]|55-6|55-6[319_264]
43-5	4837-4841	cell	object[264]|event[265]	new[264]|new[265]	_	_
43-6	4842-4854	degeneration	event[265]	new[265]	_	_
43-7	4855-4856	,	event[265]	new[265]	_	_
43-8	4857-4862	which	event[265]	new[265]	_	_
43-9	4863-4866	may	event[265]	new[265]	_	_
43-10	4867-4873	worsen	event[265]	new[265]	_	_
43-11	4874-4877	the	event[265]|abstract[266]	new[265]|new[266]	_	_
43-12	4878-4889	anaphylaxis	event[265]|abstract[266]	new[265]|new[266]	_	_
43-13	4890-4891	.	_	_	_	_

#Text=Beta-blockers should be used with extreme caution because they can exaggerate coronary spasms and cause epinephrine to be ineffective .
44-1	4892-4905	Beta-blockers	abstract	new	ana	44-9
44-2	4906-4912	should	_	_	_	_
44-3	4913-4915	be	_	_	_	_
44-4	4916-4920	used	_	_	_	_
44-5	4921-4925	with	_	_	_	_
44-6	4926-4933	extreme	abstract[268]	new[268]	_	_
44-7	4934-4941	caution	abstract[268]	new[268]	_	_
44-8	4942-4949	because	_	_	_	_
44-9	4950-4954	they	abstract	giv	_	_
44-10	4955-4958	can	_	_	_	_
44-11	4959-4969	exaggerate	_	_	_	_
44-12	4970-4978	coronary	event[270]	new[270]	_	_
44-13	4979-4985	spasms	event[270]	new[270]	_	_
44-14	4986-4989	and	_	_	_	_
44-15	4990-4995	cause	_	_	_	_
44-16	4996-5007	epinephrine	substance	new	coref	45-1
44-17	5008-5010	to	_	_	_	_
44-18	5011-5013	be	_	_	_	_
44-19	5014-5025	ineffective	_	_	_	_
44-20	5026-5027	.	_	_	_	_

#Text=Epinephrine is the only life-saving drug in the event of aggravated ischemia , vasospasm , and arrhythmias .
45-1	5028-5039	Epinephrine	substance	giv	coref	45-3[273_0]
45-2	5040-5042	is	_	_	_	_
45-3	5043-5046	the	substance[273]	giv[273]	_	_
45-4	5047-5051	only	substance[273]	giv[273]	_	_
45-5	5052-5063	life-saving	substance[273]	giv[273]	_	_
45-6	5064-5068	drug	substance[273]	giv[273]	_	_
45-7	5069-5071	in	substance[273]	giv[273]	_	_
45-8	5072-5075	the	substance[273]|event[274]	giv[273]|giv[274]	_	_
45-9	5076-5081	event	substance[273]|event[274]	giv[273]|giv[274]	_	_
45-10	5082-5084	of	substance[273]|event[274]	giv[273]|giv[274]	_	_
45-11	5085-5095	aggravated	substance[273]|event[274]|abstract[275]	giv[273]|giv[274]|new[275]	_	_
45-12	5096-5104	ischemia	substance[273]|event[274]|abstract[275]	giv[273]|giv[274]|new[275]	_	_
45-13	5105-5106	,	substance[273]|event[274]	giv[273]|giv[274]	_	_
45-14	5107-5116	vasospasm	substance[273]|event[274]|event	giv[273]|giv[274]|giv	_	_
45-15	5117-5118	,	substance[273]|event[274]	giv[273]|giv[274]	_	_
45-16	5119-5122	and	substance[273]|event[274]	giv[273]|giv[274]	_	_
45-17	5123-5134	arrhythmias	substance[273]|event[274]|abstract	giv[273]|giv[274]|new	_	_
45-18	5135-5136	.	_	_	_	_

#Text=In some animal studies , adrenaline may cause LV impairment and not recovery in established anaphylactic shock .
46-1	5137-5139	In	_	_	_	_
46-2	5140-5144	some	abstract[279]	new[279]	_	_
46-3	5145-5151	animal	animal|abstract[279]	new|new[279]	_	_
46-4	5152-5159	studies	abstract[279]	new[279]	_	_
46-5	5160-5161	,	_	_	_	_
46-6	5162-5172	adrenaline	substance	new	coref	47-3
46-7	5173-5176	may	_	_	_	_
46-8	5177-5182	cause	_	_	_	_
46-9	5183-5185	LV	object|event[282]	new|new[282]	_	_
46-10	5186-5196	impairment	event[282]	new[282]	_	_
46-11	5197-5200	and	_	_	_	_
46-12	5201-5204	not	_	_	_	_
46-13	5205-5213	recovery	event[283]	new[283]	_	_
46-14	5214-5216	in	event[283]	new[283]	_	_
46-15	5217-5228	established	event[283]|event[284]	new[283]|new[284]	_	_
46-16	5229-5241	anaphylactic	event[283]|event[284]	new[283]|new[284]	_	_
46-17	5242-5247	shock	event[283]|event[284]	new[283]|new[284]	_	_
46-18	5248-5249	.	_	_	_	_

#Text=Therefore , adrenaline is only suggested in high-grade anaphylactic reactions .
47-1	5250-5259	Therefore	_	_	_	_
47-2	5260-5261	,	_	_	_	_
47-3	5262-5272	adrenaline	substance	giv	_	_
47-4	5273-5275	is	_	_	_	_
47-5	5276-5280	only	_	_	_	_
47-6	5281-5290	suggested	_	_	_	_
47-7	5291-5293	in	_	_	_	_
47-8	5294-5304	high-grade	event[286]	new[286]	_	_
47-9	5305-5317	anaphylactic	event[286]	new[286]	_	_
47-10	5318-5327	reactions	event[286]	new[286]	_	_
47-11	5328-5329	.	_	_	_	_

#Text=Adequate fluids
48-1	5330-5338	Adequate	substance[287]	new[287]	_	_
48-2	5339-5345	fluids	substance[287]	new[287]	_	_

#Text=resuscitation and oxygen therapy are important supportive treatments for Kounis syndrome .
49-1	5346-5359	resuscitation	event	new	_	_
49-2	5360-5363	and	_	_	_	_
49-3	5364-5370	oxygen	substance|abstract[290]	new|new[290]	coref	49-6[291_290]
49-4	5371-5378	therapy	abstract[290]	new[290]	_	_
49-5	5379-5382	are	_	_	_	_
49-6	5383-5392	important	abstract[291]	giv[291]	coref	51-1[301_291]
49-7	5393-5403	supportive	abstract[291]	giv[291]	_	_
49-8	5404-5414	treatments	abstract[291]	giv[291]	_	_
49-9	5415-5418	for	abstract[291]	giv[291]	_	_
49-10	5419-5425	Kounis	abstract[291]|person|abstract[293]	giv[291]|giv|giv[293]	_	_
49-11	5426-5434	syndrome	abstract[291]|abstract[293]	giv[291]|giv[293]	_	_
49-12	5435-5436	.	_	_	_	_

#Text=Type II variant patients can take advantage of an ACS protocol .
50-1	5437-5441	Type	object[294]|object[295]|person[296]	new[294]|new[295]|giv[296]	coref	52-2[310_295]
50-2	5442-5444	II	object[294]|object[295]|person[296]	new[294]|new[295]|giv[296]	_	_
50-3	5445-5452	variant	object[295]|person[296]	new[295]|giv[296]	_	_
50-4	5453-5461	patients	person[296]	giv[296]	_	_
50-5	5462-5465	can	_	_	_	_
50-6	5466-5470	take	_	_	_	_
50-7	5471-5480	advantage	abstract[297]	new[297]	_	_
50-8	5481-5483	of	abstract[297]	new[297]	_	_
50-9	5484-5486	an	abstract[297]|abstract[299]	new[297]|new[299]	coref	52-7[312_299]
50-10	5487-5490	ACS	abstract[297]|abstract|abstract[299]	new[297]|giv|new[299]	coref	52-8
50-11	5491-5499	protocol	abstract[297]|abstract[299]	new[297]|new[299]	_	_
50-12	5500-5501	.	_	_	_	_

#Text=Double antiplatelet therapy in the pharmacological treatment of myocardial revascularization is suggested , including acetylsalicylic acid ( ASA ) and another P2Y12 receptor inhibitor .
51-1	5502-5508	Double	abstract[301]	giv[301]	_	_
51-2	5509-5521	antiplatelet	abstract|abstract[301]	new|giv[301]	_	_
51-3	5522-5529	therapy	abstract[301]	giv[301]	_	_
51-4	5530-5532	in	abstract[301]	giv[301]	_	_
51-5	5533-5536	the	abstract[301]|abstract[302]	giv[301]|new[302]	_	_
51-6	5537-5552	pharmacological	abstract[301]|abstract[302]	giv[301]|new[302]	_	_
51-7	5553-5562	treatment	abstract[301]|abstract[302]	giv[301]|new[302]	_	_
51-8	5563-5565	of	abstract[301]|abstract[302]	giv[301]|new[302]	_	_
51-9	5566-5576	myocardial	abstract[301]|abstract[302]|event[303]	giv[301]|new[302]|new[303]	coref	55-19[0_303]
51-10	5577-5594	revascularization	abstract[301]|abstract[302]|event[303]	giv[301]|new[302]|new[303]	_	_
51-11	5595-5597	is	_	_	_	_
51-12	5598-5607	suggested	_	_	_	_
51-13	5608-5609	,	_	_	_	_
51-14	5610-5619	including	_	_	_	_
51-15	5620-5635	acetylsalicylic	substance[304]	giv[304]	_	_
51-16	5636-5640	acid	substance[304]	giv[304]	_	_
51-17	5641-5642	(	_	_	_	_
51-18	5643-5646	ASA	abstract	new	_	_
51-19	5647-5648	)	_	_	_	_
51-20	5649-5652	and	_	_	_	_
51-21	5653-5660	another	abstract[308]	new[308]	_	_
51-22	5661-5666	P2Y12	substance|abstract[308]	new|new[308]	_	_
51-23	5667-5675	receptor	substance|abstract[308]	new|new[308]	_	_
51-24	5676-5685	inhibitor	abstract[308]	new[308]	_	_
51-25	5686-5687	.	_	_	_	_

#Text=In the type III variant , the ACS protocol accompanied by urgent aspiration of intrastent thrombus is suggested (
52-1	5688-5690	In	_	_	_	_
52-2	5691-5694	the	object[310]	giv[310]	_	_
52-3	5695-5699	type	abstract[309]|object[310]	new[309]|giv[310]	_	_
52-4	5700-5703	III	abstract[309]|object[310]	new[309]|giv[310]	_	_
52-5	5704-5711	variant	object[310]	giv[310]	_	_
52-6	5712-5713	,	_	_	_	_
52-7	5714-5717	the	abstract[312]	giv[312]	_	_
52-8	5718-5721	ACS	abstract|abstract[312]	giv|giv[312]	_	_
52-9	5722-5730	protocol	abstract[312]	giv[312]	_	_
52-10	5731-5742	accompanied	abstract[312]	giv[312]	_	_
52-11	5743-5745	by	abstract[312]	giv[312]	_	_
52-12	5746-5752	urgent	abstract[312]|abstract[313]	giv[312]|new[313]	_	_
52-13	5753-5763	aspiration	abstract[312]|abstract[313]	giv[312]|new[313]	_	_
52-14	5764-5766	of	abstract[312]|abstract[313]	giv[312]|new[313]	_	_
52-15	5767-5777	intrastent	abstract[312]|abstract[313]|abstract[314]	giv[312]|new[313]|new[314]	_	_
52-16	5778-5786	thrombus	abstract[312]|abstract[313]|abstract[314]	giv[312]|new[313]|new[314]	_	_
52-17	5787-5789	is	_	_	_	_
52-18	5790-5799	suggested	_	_	_	_
52-19	5800-5801	(	_	_	_	_

#Text=Figure 5
53-1	5802-5808	Figure	abstract[315]	giv[315]	_	_
53-2	5809-5810	5	abstract[315]	giv[315]	_	_

#Text=) .
54-1	5811-5812	)	_	_	_	_
54-2	5813-5814	.	_	_	_	_

#Text=Antihistamines , corticosteroids , and mast cell stabilizers may be helpful for allergic symptoms after stent implantation or revascularization .
55-1	5815-5829	Antihistamines	substance	new	_	_
55-2	5830-5831	,	_	_	_	_
55-3	5832-5847	corticosteroids	substance	giv	_	_
55-4	5848-5849	,	_	_	_	_
55-5	5850-5853	and	_	_	_	_
55-6	5854-5858	mast	object|object[319]|abstract[320]	giv|giv[319]|new[320]	_	_
55-7	5859-5863	cell	object[319]|abstract[320]	giv[319]|new[320]	_	_
55-8	5864-5875	stabilizers	abstract[320]	new[320]	_	_
55-9	5876-5879	may	_	_	_	_
55-10	5880-5882	be	_	_	_	_
55-11	5883-5890	helpful	_	_	_	_
55-12	5891-5894	for	_	_	_	_
55-13	5895-5903	allergic	abstract[321]	new[321]	_	_
55-14	5904-5912	symptoms	abstract[321]	new[321]	_	_
55-15	5913-5918	after	_	_	_	_
55-16	5919-5924	stent	abstract|event[323]	new|new[323]	_	_
55-17	5925-5937	implantation	event[323]	new[323]	_	_
55-18	5938-5940	or	_	_	_	_
55-19	5941-5958	revascularization	event	giv	_	_
55-20	5959-5960	.	_	_	_	_
